



Indian Journal of Psychiatry

OFFICIAL PUBLICATION OF THE INDIAN PSYCHIATRIC SOCIETY

ISSN 0019-5545

Volume 61, Number 3

May-June 2019

Now indexed
with PubMed
&
Covered in
Journal Citation
Reports (JCR)

EDITORIAL

Chatbots in psychiatry: Can treatment gap be lessened for psychiatric disorders in India

Om Prakash Singh

GUEST EDITORIAL

Methodologies and skills in child and adolescent mental health, psychosocial care, and protection: A repository of training and intervention materials

Sheila Ramaswamy, Shekhar Seshadri

ORIGINAL ARTICLES

Relative effectiveness of N-acetylcysteine and baclofen as anticraving agents in cannabis dependence – A retrospective study with telephonic follow-up

Venkata Lakshmi Narasimha, Lekhansh Shukla, R. P. S. Shyam, Arun Kandasamy, Vivek Benegal

Assessment of prevalence of attention deficit hyperactivity disorder among schoolchildren in selected schools

T. Golden Catherine, Nancy Grace Robert, K. Kanchana Mala, C. Kanniammal, Judie Arullapan

Mortality in schizophrenia: A study of verbal autopsy from cohorts of two rural communities of South India

Narayana Manjunatha, C. Naveen Kumar, Jagadisha Thirthalli, K. K. Suresha, D. M. Harisha, Udupi Arunachala

Young psychiatrists' opinion on the activities of Indian Psychiatric Society: A survey under the aegis of Research, Education, and Training Foundation of Indian Psychiatric Society

Sandeep Grover, Swapnajeet Sahoo, Balachander Srinivas, Adarsh Tripathi, Ajit Avasthi

Catechol-O-Methyltransferase Val158Met and brain-derived neurotrophic factor Val66Met gene polymorphisms in paraphilic sexual offenders

Mujgan Cengiz, Esma Cezayirli, Burcu Bayoglu, Hizir Asliyukse, Nese Kocabasoglu

Comparison of efficacy of ketamine versus thiopentone-assisted modified electroconvulsive therapy in major depression

Amit Jagtiani, Hitesh Khurana, Naveen Malhotra

Internet addiction and daytime sleepiness among professionals in India: A web-based survey

Lokesh Kumar Singh, K. Hari Hara Suchandra, Amrit Pattajoshi, Spoorthy Sai Mamidipalli, Huma Kamal, Sharda Singh, Bhoomika Sachacher, Varun Mehta

Assessment of cotinine in urine and saliva of smokers, passive smokers, and nonsmokers: Method validation using liquid chromatography and mass spectrometry

Priyamvada Sharma, Niharika Sane, Shrivanthi D. Anand, Marimutthu P, Vivek Benegal

Depression in caregivers of patients with breast cancer: A cross-sectional study from a cancer research center in South India

Sreeja Sahadevan, Vasudevan Nambodiri

A cross-sectional study to assess the association between major depression and inflammatory markers in patients with acute ischemic stroke

225 Hasan Hüseyin Kozak, Faruk Uğuz, İbrahim Kılınç, Ali Ulvi Uca, Osman Serhat Tokgöz, Figen Güney, Nejla Özer

BRIEF RESEARCH COMMUNICATIONS

Sample attrition rate of a community study: An analysis of Lucknow urban and rural elderly follow-up over a period of 9 years

226 Bhupendra Singh, Nisha Mani Pandey, R. K. Garg, Neera Kohli, Kausar Usman, G. G. Agarwal, Sarvada Chandra Tiwari

Measuring reliability and validity of "Stressometer[®]": A computer-based mass screening and assessment tool for evaluation of stress level and sources of stressors

228 Sandeep Vohra, Angela Swilley Kelling, Mrinal Mugdh Varma, Anand Prakash, Divyani Khurana

CME

Assessment and management of pediatric depression

232 Suravi Patra

CASE REPORTS

Haloperidol-related neutropenia

238 Ebru Şahan

Risperidone as an effective choice for obsessive-compulsive symptoms and tardive dyskinesia in an Indian quadragenarian with schizo-obsessive disorder

244 Ajita S. Nayak, Heena H. Merchant, Hrishikesh B. Nachane, Aditya R. Anvekar

LETTERS TO EDITOR

Blood urea levels associated to antidepressant drug treatment: Role of nitrogen and nitric oxide

253 Roberto Lozano, Reyes Marin, Maria-Jesus Santacruz, Alberto-José Frutos

Rapidly progressive dementia in a case of progressive multifocal leukoencephalopathy

258 Partha Pratim Daimary, Soumitra Das, Seshadri Sekhar Chatterjee, Rammohan Krishnapillai

A case of pathological gambling

265 Neha Sharma, Anindya Kumar Gupta, T. Hannah Jane

Escitalopram-induced extrapyramidal symptoms

265 Pattath Narayanan Suresh Kumar, Arun Gopala Krishnan, Rohith Suresh

Integrating mental health into primary care for addressing depression in a rural population: An experience from North India

270 M. A. Bashir, Aseem Mehra, Arun K. Aggarwal

LITERARY PSYCHIATRY

Golden Brown Jubilee: 25 Years of Trainspotting by Irvine Welsh

277 (Maj) Ashutosh Ratnam



Online at
www.indianjpsychiatry.org

Escitalopram-induced extrapyramidal symptoms

Sir,

Serotonin-specific reuptake inhibitors (SSRIs) are widely used for a variety of clinical conditions due to their relatively safe side-effect profile. Among the various classes of antidepressants, SSRIs are the common offenders producing extrapyramidal symptoms (EPSs). The incidence of EPS is high with escitalopram (12%) followed by sertraline (11%), paroxetine (10%), and fluoxetine (8%).^[1] The SSRIs produces reversible or irreversible motor disturbances through pathophysiological changes in basal ganglion motor system by altering the dopamine receptors postsynaptically.^[2]

A 34-year-old female presented with complaints of sadness of mood, crying spells, feeling lonely, decreased interest in day-to-day activities, lethargy and disturbed biological functions for the last 6 months. Her past and family history and personal history was noncontributory. General and systemic examination was within normal limits. Mental status examination revealed decreased psychomotor activity, depressed affect, depressive cognitions with well-preserved insight. A diagnosis of moderate depressive disorder was made, and she was started on escitalopram 10 mg/day along with clonazepam 0.5 mg at night time. She was maintaining well and escitalopram 10 mg was continued for the next 18 months as per patient's request. 18th month, she presented with complaints of slurring of speech, drooling of saliva, decreased bodily movements, and slowness in walking. Neurological examination revealed bradykinesia, cogwheel rigidity, dysarthric speech, and tremor of hands. Routine biochemical tests and head MRI, EEG were done and were found to be normal. No history of any other drug use/abuse, head injury, seizures,

fever or movement disorder was reported. A diagnosis of escitalopram-induced acute extrapyramidal syndrome was made after excluding other possible causes. Escitalopram was immediately discontinued, the patient was reassured, and trihexyphenidyl 2 mg bid was started. Follow-up after 2 weeks reported significant improvement. Subsequently trihexyphenidyl was stopped and dothiepin 50 mg/day was started to control the depressive symptoms. The patient was followed-up for the next 6 months without any symptom recurrence. The Naranjo probability scale applied retrospectively revealed a score of 6, pointing to a "probable" drug reaction.

The data for escitalopram-induced EPS is rare except in few cases.^[3,4] The potential risk factors for EPS induced by antidepressants are advancing age, female gender, preexisting extrapyramidal disorder, other concurrent neuroleptic medications and pharmacokinetic interaction through CYP2D6 inhibition.^[1] Other than the female gender, none of these risk factors were present in our patient. Researchers have extrapolated a link between antidepressant-induced EPS and the CYP2D6 phenotype. On analyzing the risk factors for these reactions during treatment with SSRIs, including the CYP2D6 phenotype, serotonin, and dopamine transporter and receptor polymorphisms, it was noted that the risk of EPS with SSRIs seemed to increase with advanced age and the presence of the A1 allele of the dopamine D2 receptor gene Taq1A.^[5]

Being a young patient, the possibility of young-onset parkinsonian disease was considered in which, family history of parkinsonism is an important risk factor.^[6] Our patient's history was not significant for

either parkinsonism or any other movement disorder. In rat models of EPS induced by SSRIs, a specific effect on tyrosine hydroxylase, which is a speed-limiting enzyme of dopamine synthesis in substantia nigra has been reported. Tyrosine hydroxylase synthesis was significantly decreased by SSRIs in substantia nigra, and the serotonin transporter (SERT) inhibition can activate microglia and alter the regulation of tyrosine hydroxylase, the rate-limiting enzyme for dopamine biosynthesis, and these changes may play a role in mediating the EPS associated with SERT inhibitors.^[7]

Drug-induced parkinsonism (DIP) may represent a preexisting vulnerability to future Parkinson's disease. Treatment of DIP involves discontinuation of the offending drugs, which usually promotes remission of the parkinsonian syndrome within a short time, although parkinsonism may sometimes persist and require dopaminergic treatment. One atypical feature in our patient was that compared to previously reported cases where EPS developed few weeks after initiation of escitalopram, in the index patient EPS developed only 2 years after starting escitalopram. However, the EPS was reversed after a short course of anticholinergic treatment. The reason for late onset of EPS needs further exploration. This is an attempt to create an awareness of drug-induced EPS as adverse reaction in patients taking escitalopram even after months or years of therapy so that timely recognition can prevent such adverse effects.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

**Pattath Narayanan Suresh Kumar,
Arun Gopala Krishnan¹, Rohith Suresh²**

Department of Psychiatry, KMCT Medical College,

¹Department of Psychiatry, PVS Hospital, Calicut,


²Department of Medicine, Government Medical College,
Kochi, Kerala, India.

E-mail: drpnsuresh@gmail.com

REFERENCES

1. Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyrarnidal symptoms associated with antidepressants – A review of the literature and an analysis of spontaneous reports. *Ann Clin Psychiatry* 2010;22:148-56.
2. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. *J Psychopharmacol* 1998;12:192-214.
3. Dixit S, Khan SA, Azad S. A case of SSRI induced irreversible Parkinsonism. *J Clin Diagn Res* 2015;9:VD01-2.
4. Dave-Momin N, Lokhande C, Shah N, Desousa A. Escitalopram induced dystonia: A case report. *Int J Toxicol Pharmacol Res* 2014;6:20-1.
5. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. *J Clin Psychopharmacol* 2006;26:192-7.
6. Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited – Clinical features, natural history, and mortality. *Mov Disord* 1998;13:885-94.
7. MacGillivray L, Reynolds KB, Sickand M, Rosebush PI, Mazurek MF. Inhibition of the serotonin transporter induces microglial activation and downregulation of dopaminergic neurons in the substantia nigra. *Synapse* 2011;65:1166-72.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
Website: www.indianjpsychiatry.org	Quick Response Code 
DOI: 10.4103/psychiatry.IndianJPsychiatry_331_18	

How to cite this article: Kumar PN, Krishnan AG, Suresh R. Escitalopram-induced extrapyramidal symptoms. *Indian J Psychiatry* 2019;61:318-9.

© 2019 Indian Journal of Psychiatry | Published by Wolters Kluwer - Medknow